Popular drugs like Ozemic and Monjauro aid in managing diabetes by lowering blood sugar levels. They have surged in ...

Novo Nordisk (NVO) reported better-than-expected operating profits for Q4 2024 on Wednesday, thanks mainly to its GLP-1 drugs, including its popular weight loss therapy Wegovy, which added DKK 19.9B ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Rising consumer demand for fewer empty calories is pushing the snack and beverage giant to offer options with less sodium, fat and artificial ingredients.